May 1, 2012 | last updated June 1, 2012 2:15 pm

Yale, GlaxoSmithKline partner on research collaborative

GlaxoSmithKline and Yale University have established a new drug discovery research collaboration to design a potential new class of medicines that kill disease-causing proteins.

Under the agreement, a joint research team will work to show that Yale's pioneering work on proteolysis targeting chimeric molecules, or PROTACs, can be turned into future medicine. PROTAC technology guides disease-causing proteins to a cell's "garbage disposal" where they can be destroyed.

Mutant or higher-than normal amounts of these proteins typically drive disease progression in areas such as oncology, inflammation and infections; yet many cannot be tackled by traditional ways of making drugs.

If successful, GlaxoSmithKline will have the right to use this technology for multiple disease-causing proteins across all therapy areas.

For each protein-degrading drug that is discovered and developed, Yale will be eligible for milestone and royalty payments.


Type your comment here:

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll
Most Popular on Facebook
Copyright 2017 New England Business Media